Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.
Creabilis, a Luxembourg-based firm focused solely on itching (chronic pruritus), said patients receiving CT327 showed a significant reduction in pruritus, measured using VAS (Visual Analogue Scale) – "an accepted regulatory...